The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The GLP-1 Receptor Agonist Market Projected To Become By 2030 Based On Its 2026 Valuation?
The market size for GLP-1 receptor agonists has demonstrated robust expansion over the past few years. This market is projected to expand from $14.09 billion in 2025 to $14.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. Historically, this growth has been driven by factors such as the increasing incidence of type 2 diabetes, greater understanding of glycemic control treatments, superior clinical effectiveness compared to conventional antidiabetic drugs, healthcare providers’ inclination towards incretin-based treatments, and supportive reimbursement policies in advanced economies.
The glp-1 receptor agonist market is anticipated to experience substantial growth in the coming years. It is projected to expand to $18.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. The projected expansion during this period stems from factors such as an increasing global obesity population, wider approvals for cardiovascular risk reduction, advancements in oral and combination therapies, greater market penetration in developing markets, and an escalating patient preference for weight loss advantages. Significant trends for the forecast period include the diversification of glp-1 therapies beyond diabetes, a growing demand for long-acting and once-weekly formulations, the emergence of oral glp-1 receptor agonists, an intensified focus on weight management indications, and the establishment of strategic partnerships and licensing agreements.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The GLP-1 Receptor Agonist Market?
An anticipated increase in diabetes cases is projected to advance the GLP-1 receptor agonist market in the coming years. Diabetes is a long-term condition that develops when the pancreas either produces insufficient amounts of insulin or the body cannot properly utilize the insulin it produces. High blood sugar is a characteristic symptom of this metabolic disorder, diabetes mellitus. GLP-1 receptor agonists are utilized in diabetes management to stimulate the body to generate more insulin, which aids in lowering blood sugar levels, thus the growing prevalence of diabetes will drive market expansion. For instance, in March 2024, figures from the Office for Health Improvement and Disparities, a UK-based government department, showed that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes saw a 22% increase, and for type 2 diabetes, it rose by 21%, while the percentage achieving target HbA1c levels increased to 37.9%. Consequently, the increasing prevalence of diabetes is a key factor propelling the GLP-1 receptor agonist market.
What Segment Groups Are Identified Within The GLP-1 Receptor Agonist Market?
The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
What Trends Are Advancing Progress In The GLP-1 Receptor Agonist Market?
Major companies operating in the GLP-1 receptor agonist market are prioritizing the development of sustained-release GLP-1 receptor agonists to secure a competitive advantage. These sustained-release GLP-1 receptor agonists (GLP-1RAs) are a class of medication that slowly releases GLP-1RA into the bloodstream over time, leading to extended effects and less frequent injections compared to traditional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a pharmaceuticals company from Japan, launched Mounjaro 2.5 mg or 5 mg Ateos. This represents the world’s first sustained-release GIP/GLP-1 receptor agonist designed for the treatment of type 2 diabetes, activating both the GLP-1 and GIP receptors. The GLP-1 receptor is instrumental in regulating blood sugar levels, whereas the GIP receptor is involved in promoting insulin secretion and reducing appetite.
Which Companies Hold Significant Positions In The GLP-1 Receptor Agonist Market?
Major companies operating in the glp-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.
Read the full glp-1 receptor agonist market report here:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
Which Regions Are Projected To Dominate The GLP-1 Receptor Agonist Market In The Coming Years?
North America was the largest region in the GLP-1 receptor agonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored GLP-1 Receptor Agonist Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp
Browse Through More Reports Similar to the Global GLP-1 Receptor Agonist Market 2026, By The Business Research Company
Glp 1 Receptor Agonist Market Report 2026
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
G Protein Coupled Receptors Market Report 2026
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report
Glucagon Like Peptide 1 Market Report 2026
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model